Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 16;328(7):652-662.
doi: 10.1001/jama.2022.12841.

Trends in Active Treatment of Live-born Neonates Between 22 Weeks 0 Days and 25 Weeks 6 Days by Gestational Age and Maternal Race and Ethnicity in the US, 2014 to 2020

Affiliations

Trends in Active Treatment of Live-born Neonates Between 22 Weeks 0 Days and 25 Weeks 6 Days by Gestational Age and Maternal Race and Ethnicity in the US, 2014 to 2020

Kartik K Venkatesh et al. JAMA. .

Abstract

Importance: Birth in the periviable period between 22 weeks 0 days and 25 weeks 6 days' gestation is a major source of neonatal morbidity and mortality, and the decision to initiate active life-saving treatment is challenging.

Objective: To assess whether the frequency of active treatment among live-born neonates in the periviable period has changed over time and whether active treatment differed by gestational age at birth and race and ethnicity.

Design, setting, and participants: Serial cross-sectional descriptive study using National Center for Health Statistics natality data from 2014 to 2020 for 61 908 singleton live births without clinical anomalies between 22 weeks 0 days and 25 weeks 6 days in the US.

Exposures: Year of delivery, gestational age at birth, and race and ethnicity of the pregnant individual, stratified as non-Hispanic Asian/Pacific Islander, non-Hispanic Black, Hispanic/Latina, and non-Hispanic White.

Main outcomes and measures: Active treatment, determined by whether there was an attempt to treat the neonate and defined as a composite of surfactant therapy, immediate assisted ventilation at birth, assisted ventilation more than 6 hours in duration, and/or antibiotic therapy. Frequencies, mean annual percent change (APC), and adjusted risk ratios (aRRs) were estimated.

Results: Of 26 986 716 live births, 61 908 (0.2%) were periviable live births included in this study: 5% were Asian/Pacific Islander, 37% Black, 24% Hispanic, and 34% White; and 14% were born at 22 weeks, 21% at 23 weeks, 30% at 24 weeks, and 34% at 25 weeks. Fifty-two percent of neonates received active treatment. From 2014 to 2020, the overall frequency (mean APC per year) of active treatment increased significantly (3.9% [95% CI, 3.0% to 4.9%]), as well as among all racial and ethnic subgroups (Asian/Pacific Islander: 3.4% [95% CI, 0.8% to 6.0%]); Black: 4.7% [95% CI, 3.4% to 5.9%]; Hispanic: 4.7% [95% CI, 3.4% to 5.9%]; and White: 3.1% [95% CI, 1.1% to 4.4%]) and among each gestational age range (22 weeks: 14.4% [95% CI, 11.1% to 17.7%] and 25 weeks: 2.9% [95% CI, 1.5% to 4.2%]). Compared with neonates born to White individuals (57.0%), neonates born to Asian/Pacific Islander (46.2%; risk difference [RD], -10.81 [95% CI, -12.75 to -8.88]; aRR, 0.82 [95% CI, [0.79-0.86]), Black (51.6%; RD, -5.42 [95% CI, -6.36 to -4.50]; aRR, 0.90 [95% CI, 0.89 to 0.92]), and Hispanic (48.0%; RD, -9.03 [95% CI, -10.07 to -7.99]; aRR, 0.83 [95% CI, 0.81 to 0.85]) individuals were significantly less likely to receive active treatment.

Conclusions and relevance: From 2014 to 2020 in the US, the frequency of active treatment among neonates born alive between 22 weeks 0 days and 25 weeks 6 days significantly increased, and there were differences in rates of active treatment by race and ethnicity.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Costantine reported receiving grants from the National Institutes of Health (NIH), Baxter International, and Siemens Healthcare and receiving personal fees from Progenity. Dr Khan reported receiving grants from the American Heart Association (19TPA34890060) and the NIH (U01HL160279, R01HL159250). No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Birth Records Included of Singleton Nonanomalous Neonates Live-born in the Periviable Period Between 22 Weeks 0 Days and 25 Weeks 6 Days’ Gestation, US Natality Files, 2014-2020
aN = 947 excluded for missing race and ethnicity data and n = 2447 excluded for race and ethnicity other than non-Hispanic White, Hispanic/Latina, non-Hispanic Black, non-Hispanic Asian/Pacific Islander (of which 488 were non-Hispanic American Indian).
Figure 2.
Figure 2.. Frequency (per 100 Live Births) of Active Treatment of Neonates Live-born in the Periviable Period Between 22 Weeks 0 Days and 25 Weeks 6 Days’ Gestation by Maternal Race and Ethnicity and Gestational Age at Delivery
Figure 3.
Figure 3.. Association Between Maternal Race and Ethnicity and Active Treatment of Neonates Live-born in the Periviable Period Between 22 Weeks 0 Days and 25 Weeks 6 Days’ Gestation Overall and by Gestational Age at Delivery, US Natality Files, 2014-2020
Baseline comparison is with non-Hispanic White. RR indicates relative risk. aModel adjusted for mother’s age, parity, prepregnancy body mass index, health insurance, education, receipt of prenatal care, chronic hypertension, gestational hypertension and/or preeclampsia, pregestational or gestational diabetes, chorioamnionitis, birthweight, sex, and year. bP value for the interaction of maternal race and ethnicity (referent, White individuals) with year of delivery in the adjusted model.

Comment in

References

    1. Hamilton BE, Martin JA, Osterman MJ, Curtin SC, Matthews TJ. Births: final data for 2014. Natl Vital Stat Rep. 2015;64(12):1-64. - PubMed
    1. Salihu HM, Salinas-Miranda AA, Hill L, Chandler K. Survival of pre-viable preterm infants in the United States: a systematic review and meta-analysis. Semin Perinatol. 2013;37(6):389-400. doi:10.1053/j.semperi.2013.06.021 - DOI - PubMed
    1. Ananth CV, Chauhan SP. Epidemiology of periviable births: the impact and neonatal outcomes of twin pregnancy. Clin Perinatol. 2017;44(2):333-345. doi:10.1016/j.clp.2017.01.002 - DOI - PubMed
    1. Tucker Edmonds B, Savage TA, Kimura RE, et al. . Prospective parents’ perspectives on antenatal decision making for the anticipated birth of a periviable infant. J Matern Fetal Neonatal Med. 2019;32(5):820-825. doi:10.1080/14767058.2017.1393066 - DOI - PMC - PubMed
    1. Brunkhorst J, Weiner J, Lantos J. Infants of borderline viability: the ethics of delivery room care. Semin Fetal Neonatal Med. 2014;19(5):290-295. doi:10.1016/j.siny.2014.08.001 - DOI - PubMed

MeSH terms